卡格列净:用于治疗2型糖尿病的SGLT2抑制剂

Future Prescriber Pub Date : 2013-08-01 DOI:10.1002/fps.101

Richard Donnelly PhD, MD, FRCP, FRACP

{"title":"卡格列净:用于治疗2型糖尿病的SGLT2抑制剂","authors":"Richard Donnelly PhD, MD, FRCP, FRACP","doi":"10.1002/fps.101","DOIUrl":null,"url":null,"abstract":"<p>Canagliflozin is a sodium-glucose transporter protein inhibitor under development for the treatment of type 2 diabetes mellitus; it reduces circulatory glucose by facilitating its urinary excretion. In this Drug profile, Richard Donnelly discusses the need for drugs with a mode of action independent of insulin and considers the efficacy and tolerability of canagliflozin in clinical trials, to date, as well as its potential place in management. Copyright © 2013 John Wiley & Sons, Ltd.</p>","PeriodicalId":100566,"journal":{"name":"Future Prescriber","volume":"14 1","pages":"5-7"},"PeriodicalIF":0.0000,"publicationDate":"2013-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1002/fps.101","citationCount":"0","resultStr":"{\"title\":\"Canagliflozin: SGLT2 inhibitor for treating type 2 diabetes\",\"authors\":\"Richard Donnelly PhD, MD, FRCP, FRACP\",\"doi\":\"10.1002/fps.101\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p>Canagliflozin is a sodium-glucose transporter protein inhibitor under development for the treatment of type 2 diabetes mellitus; it reduces circulatory glucose by facilitating its urinary excretion. In this Drug profile, Richard Donnelly discusses the need for drugs with a mode of action independent of insulin and considers the efficacy and tolerability of canagliflozin in clinical trials, to date, as well as its potential place in management. Copyright © 2013 John Wiley & Sons, Ltd.</p>\",\"PeriodicalId\":100566,\"journal\":{\"name\":\"Future Prescriber\",\"volume\":\"14 1\",\"pages\":\"5-7\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2013-08-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://sci-hub-pdf.com/10.1002/fps.101\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Future Prescriber\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://onlinelibrary.wiley.com/doi/10.1002/fps.101\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Future Prescriber","FirstCategoryId":"1085","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/fps.101","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 0

摘要

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Canagliflozin: SGLT2 inhibitor for treating type 2 diabetes

Canagliflozin is a sodium-glucose transporter protein inhibitor under development for the treatment of type 2 diabetes mellitus; it reduces circulatory glucose by facilitating its urinary excretion. In this Drug profile, Richard Donnelly discusses the need for drugs with a mode of action independent of insulin and considers the efficacy and tolerability of canagliflozin in clinical trials, to date, as well as its potential place in management. Copyright © 2013 John Wiley & Sons, Ltd.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Future Prescriber

自引率

0.00%

发文量